Precision Biosciences (DTIL) Change in Receivables (2018 - 2026)
Precision Biosciences (DTIL) reported Change in Receivables of $4.0 million for Q1 2026, up 1877.78% year-over-year from $202247.2 in Q1 2025, and up 100100.0% on a QoQ basis from -$4000.0 in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Change in Receivables data on file, last reported at $4.0 million in Q1 2026.
- Quarterly Change in Receivables rose 1877.78% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 1135.23% YoY) and the FY2025 annual result came in at -$229000.0, up 65.92% from the prior year.
- Change in Receivables advanced to $4.0 million in Q1 2026 per DTIL's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $4.0 million in Q1 2026 and bottomed at -$49.8 million in Q3 2022.
- The 5-year median for Change in Receivables is -$19000.0 (2024), against an average of -$3.1 million.
- The widest annual swing landed in 2023, when Change in Receivables slumped 51940.0%; it then soared 1877.78% in 2026.
- Tracing DTIL's Change in Receivables over 5 years: stood at $5000.0 in 2022, then tumbled by 51940.0% to -$2.6 million in 2023, then jumped by 101.58% to $41000.0 in 2024, then slumped by 109.76% to -$4000.0 in 2025, then soared by 100100.0% to $4.0 million in 2026.
- Per Business Quant, the three latest DTIL Change in Receivables figures stand at $4.0 million (Q1 2026), -$4000.0 (Q4 2025), and $4000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Mar 31, 2024 | -511,000.00 |
| Mar 31, 2024 | -511,000.00 |
| Dec 31, 2023 | -2.59 Mn |
| Dec 31, 2023 | -2.59 Mn |
| Sep 30, 2023 | 2.84 Mn |
| Sep 30, 2023 | 2.84 Mn |
| Jun 30, 2023 | -42,000.00 |
| Jun 30, 2023 | -42,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Sep 30, 2022 | -49.79 Mn |
| Sep 30, 2022 | -49.79 Mn |
| Jun 30, 2021 | -18.78 Mn |
| Jun 30, 2021 | -18.78 Mn |
| Mar 31, 2021 | 9.26 Mn |
| Mar 31, 2021 | 9.26 Mn |
| Dec 31, 2020 | -116,000.00 |
| Dec 31, 2020 | -116,000.00 |
| Sep 30, 2020 | 10.03 Mn |
| Sep 30, 2020 | 10.03 Mn |
| Jun 30, 2020 | -3.78 Mn |
| Jun 30, 2020 | -3.78 Mn |
| Mar 31, 2020 | 2.89 Mn |
| Mar 31, 2020 | 2.89 Mn |
| Dec 31, 2019 | 714,000.00 |
| Dec 31, 2019 | 714,000.00 |
| Jun 30, 2019 | -5.91 Mn |
| Jun 30, 2019 | -5.91 Mn |
| Mar 31, 2019 | 5.63 Mn |
| Mar 31, 2019 | 5.63 Mn |
| Dec 31, 2018 | -6.00 Mn |
| Dec 31, 2018 | -6.00 Mn |